Brokerages Set Olema Pharmaceuticals, Inc. (NASDAQ:OLMA) Price Target at $27.00

Olema Pharmaceuticals, Inc. (NASDAQ:OLMA) has been given an average recommendation of “Buy” by the six brokerages that are presently covering the stock, MarketBeat reports. Six analysts have rated the stock with a buy recommendation. The average 1-year target price among brokers that have covered the stock in the last year is $27.00.

A number of research analysts have recently weighed in on the company. Oppenheimer reiterated an “outperform” rating and set a $30.00 price target on shares of Olema Pharmaceuticals in a report on Wednesday, August 7th. HC Wainwright reaffirmed a “buy” rating and set a $30.00 target price on shares of Olema Pharmaceuticals in a research note on Wednesday, November 13th. Finally, JPMorgan Chase & Co. reduced their price target on shares of Olema Pharmaceuticals from $33.00 to $31.00 and set an “overweight” rating for the company in a research report on Thursday, August 8th.

Hedge Funds Weigh In On Olema Pharmaceuticals

Several institutional investors have recently bought and sold shares of OLMA. Ensign Peak Advisors Inc boosted its holdings in shares of Olema Pharmaceuticals by 6.1% during the 2nd quarter. Ensign Peak Advisors Inc now owns 14,849 shares of the company’s stock worth $161,000 after buying an additional 850 shares during the period. California State Teachers Retirement System boosted its holdings in Olema Pharmaceuticals by 3.4% during the first quarter. California State Teachers Retirement System now owns 34,695 shares of the company’s stock valued at $393,000 after acquiring an additional 1,132 shares during the period. Price T Rowe Associates Inc. MD grew its position in shares of Olema Pharmaceuticals by 6.0% in the first quarter. Price T Rowe Associates Inc. MD now owns 26,251 shares of the company’s stock valued at $298,000 after purchasing an additional 1,486 shares during the last quarter. ClariVest Asset Management LLC increased its stake in shares of Olema Pharmaceuticals by 3.1% in the second quarter. ClariVest Asset Management LLC now owns 63,149 shares of the company’s stock worth $683,000 after purchasing an additional 1,881 shares during the period. Finally, EP Wealth Advisors LLC lifted its position in shares of Olema Pharmaceuticals by 5.2% during the 3rd quarter. EP Wealth Advisors LLC now owns 48,655 shares of the company’s stock worth $581,000 after purchasing an additional 2,407 shares during the last quarter. 91.78% of the stock is currently owned by institutional investors.

Olema Pharmaceuticals Stock Performance

NASDAQ OLMA opened at $10.12 on Wednesday. The firm’s 50 day moving average price is $11.30 and its two-hundred day moving average price is $11.90. Olema Pharmaceuticals has a twelve month low of $7.68 and a twelve month high of $16.77. The stock has a market cap of $579.86 million, a price-to-earnings ratio of -4.62 and a beta of 2.02.

Olema Pharmaceuticals Company Profile

Olema Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for women’s cancers. Its lead product candidate is OP-1250, an estrogen receptor (ER) antagonist and a selective ER degrader, which is in Phase 3 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive, human epidermal growth factor receptor 2-negative breast cancer; and OP-1250 combine with CDK4/6 inhibitors palbociclib, ribociclib, and alpelisib in Phase 1/2 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive human epidermal growth factor receptor 2-negative breast cancer, as well as develops OPERA-01 for the of ER+/HER2- advanced or metastatic breast cancer.